{
    "title": "114_hr2416",
    "content": "SECTION 1. UTILIZING EVIDENCE FROM CLINICAL EXPERIENCE.\n\n    Chapter V of the Federal Food, Drug, and Cosmetic Act is amended by \ninserting after section 505E of such Act (21 U.S.C. 355f) the \nfollowing:\n\n``SEC. 505F. UTILIZING EVIDENCE FROM CLINICAL EXPERIENCE.\n\n    ``(a) In General.--The Secretary shall establish a program to \nevaluate the potential use of evidence from clinical experience--\n            ``(1) to help support the approval of a new indication for \n        a drug approved under section 505(b); and\n            ``(2) to help support or satisfy post-approval study \n        requirements.\n    ``(b) Evidence From Clinical Experience Defined.--In this section, \nthe term `evidence from clinical experience' means data regarding the \nusage, or potential benefits or risks, of a drug derived from sources \nother than randomized clinical trials, including from observational \nstudies, registries, and therapeutic use.\n    ``(c) Program Framework.--\n            ``(1) In general.--Not later than 18 months after the date \n        of enactment of this section, the Secretary shall establish a \n        draft framework for implementation of the program under this \n        section.\n            ``(2) Contents of framework.--The framework shall include \n        information describing--\n                    ``(A) the current sources of data developed through \n                clinical experience, including ongoing safety \n                surveillance, registry, claims, and patient-centered \n                outcomes research activities;\n                    ``(B) the gaps in current data collection \n                activities;\n                    ``(C) the current standards and methodologies for \n                collection and analysis of data generated through \n                clinical experience; and\n                    ``(D) the priority areas, remaining challenges, and \n                potential pilot opportunities that the program \n                established under this section will address.\n            ``(3) Consultation.--\n                    ``(A) In general.--In developing the program \n                framework under this subsection, the Secretary shall \n                consult with regulated industry, academia, medical \n                professional organizations, representatives of patient \n                advocacy organizations, disease research foundations, \n                and other interested parties.\n                    ``(B) Process.--The consultation under subparagraph \n                (A) may be carried out through approaches such as--\n                            ``(i) a public-private partnership with the \n                        entities described in such subparagraph, in \n                        which the Secretary may participate; or\n                            ``(ii) a contract, grant, or other \n                        arrangement, as determined appropriate by the \n                        Secretary with such a partnership or an \n                        independent research organization.\n    ``(d) Program Implementation.--The Secretary shall, not later than \n24 months after the date of enactment of this section and in accordance \nwith the framework established under subsection (c), implement the \nprogram to evaluate the potential use of evidence from clinical \nexperience.\n    ``(e) Guidance for Industry.--The Secretary shall--\n            ``(1) utilize the program established in subsection (d), \n        its activities, and any subsequent pilots or written reports, \n        to inform a guidance for industry on--\n                    ``(A) the circumstances under which sponsors of \n                drugs and the Secretary may rely on evidence from \n                clinical experience for the purposes described in \n                subsections (a)(1) or (a)(2); and\n                    ``(B) the appropriate standards and methodologies \n                for collection and analysis of evidence from clinical \n                experience submitted for such purposes;\n            ``(2) not later than 36 months after the date of enactment \n        of this section, issue draft guidance for industry as described \n        in paragraph (1); and\n            ``(3) not later than 48 months after the date of enactment \n        of this section, after providing an opportunity for public \n        comment on the draft guidance, issue final guidance.\n    ``(f) Rule of Construction.--\n            ``(1) Subject to paragraph (2), nothing in this section \n        prohibits the Secretary from using evidence from clinical \n        experience for purposes not specified in this section, provided \n        the Secretary determines that sufficient basis exists for any \n        such non-specified use.\n            ``(2) This section shall not be construed to alter--\n                    ``(A) the standards of evidence under--\n                            ``(i) subsection (c) or (d) of section 505, \n                        including the substantial evidence standard in \n                        such subsection (d); or\n                            ``(ii) section 351(a) of the Public Health \n                        Service Act; or\n                    ``(B) the Secretary's authority to require post-\n                approval studies or clinical trials, or the standards \n                of evidence under which studies or trials are \n                evaluated.''."
}